CONMED Corporation (CNMD)
Return on equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 64,459 | -80,582 | 62,542 | 9,517 | 28,620 |
| Total stockholders’ equity | US$ in thousands | 834,222 | 745,545 | 785,435 | 709,038 | 710,467 |
| ROE | 7.73% | -10.81% | 7.96% | 1.34% | 4.03% |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $64,459K ÷ $834,222K
= 7.73%
Conmed Corp.'s return on equity (ROE) has varied over the past five years. In 2023, the company's ROE stood at 7.73%, marking a positive increase compared to the previous year where it was -10.81%, indicating a significant improvement in the company's profitability and efficiency in generating returns for its shareholders.
Looking further back, in 2022, the negative ROE of -10.81% suggests that the company experienced a period of underperformance and inefficiency in its operations, resulting in a net loss for shareholders. However, in 2021, the company rebounded with an ROE of 7.96%, indicating a return to profitability and a positive trend in generating shareholder value.
In 2020 and 2019, Conmed Corp.'s ROE was 1.34% and 4.03%, respectively, showing modest profitability levels in those years. Overall, the fluctuating ROE figures indicate that Conmed Corp. has experienced both challenges and successes in its ability to utilize shareholders' equity effectively to generate profits throughout the analyzed period.
Peer comparison
Dec 31, 2023